Coronavirus: Moderna confirms its vaccine works against UK and South African variants
Firm working ‘out of abundance of caution’ after research suggests vaccine less effective against strain
Firm working ‘out of abundance of caution’ after research suggests vaccine less effective against strain
Regulator backs third jab, but none of the 17m doses ordered will be available until spring
European Medicines Agency approves Moderna coronavirus vaccine
The global race to create vaccines against the novel coronavirus has entered a critical stretch, with Pfizer and Moderna releasing very promising final trial data that has raised the hopes of nations struggling to fight the pandemic. Pfizer, which reported 95% efficacy, has now sought early regulatory approval.
Moderna becomes second firm to reveal positive results with nearly 95% protection in trials.
Vaccine trials 'encouraging' says WHO
Moderna said on Wednesday that it has enough data to begin its first planned interim analysis from the late-stage trial of its experimental COVID-19 vaccine, a potential step toward establishing the vaccine's efficacy.
The price set by the US pharmaceutical company is above the $ 19.50 (16.5 euros) that he advanced Pfizer for the vaccine that develops together with the German BioNTech and which is, as in the case of Moderna, at the beginning of phase 3. It is also immensely higher than the cost it has set AstraZeneca, which collaborates with the Oxford University, for Germany, Italy, France and the Netherlands: between 3 and 4 dollars (2.5 and 3.4 euros) per dose.
Massachusetts-based company began Phase III of vaccine trial earlier Monday